Patents by Inventor Andrew M. Blumenfeld

Andrew M. Blumenfeld has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20120245096
    Abstract: Botulinum toxin, among other presynaptic neurotoxins is used for the treatment and prevention of migraine and other headaches associated with vascular disorders. Presynaptic neurotoxins are delivered focally, targeting the nerve endings of the trigeminal nerve, the occipital nerve and the intranasal terminals of the parasympathetic fibers originating in the Sphenopalatine ganglion. The administration preferably targets the extracranial nerve endings of the trigeminal nerve in the temporal area, the extracranial occipital nerve endings in the occipital area, and the intranasal terminals of the trigeminal nerve and parasympathetic fibers originating in the Sphenopalatine ganglion. The delivery is carried out by way of injection or topically.
    Type: Application
    Filed: May 17, 2012
    Publication date: September 27, 2012
    Applicant: ALLERGAN, INC.
    Inventor: Andrew M. Blumenfeld
  • Patent number: 8241641
    Abstract: Botulinum toxin, among other presynaptic neurotoxins is used for the treatment and prevention of migraine and other headaches associated with vascular disorders. Presynaptic neurotoxins are delivered focally, targeting the nerve endings of the trigeminal nerve, the occipital nerve and the intranasal terminals of the parasympathetic fibers originating in the Sphenopalatine ganglion. The administration preferably targets the extracranial nerve endings of the trigeminal nerve in the temporal area, the extracranial occipital nerve endings in the occipital area, and the intranasal terminals of the trigeminal nerve and parasympathetic fibers originating in the Sphenopalatine ganglion. The delivery is carried out by way of injection or topically.
    Type: Grant
    Filed: December 18, 2009
    Date of Patent: August 14, 2012
    Assignee: Allergan, Inc.
    Inventor: Andrew M. Blumenfeld
  • Publication number: 20120040911
    Abstract: Botulinum toxin, among other presynaptic neurotoxins is used for the treatment and prevention of migraine and other headaches associated with vascular disorders. Presynaptic neurotoxins are delivered focally, targeting the nerve endings of the trigeminal nerve, the occipital nerve and the intranasal terminals of the parasympathetic fibers originating in the Sphenopalatine ganglion. The administration preferably targets the extracranial nerve endings of the trigeminal nerve in the temporal area, the extracranial occipital nerve endings in the occipital area, and the intranasal terminals of the trigeminal nerve and parasympathetic fibers originating in the Sphenopalatine ganglion. The delivery is carried out by way of injection or topically.
    Type: Application
    Filed: December 18, 2009
    Publication date: February 16, 2012
    Inventor: ANDREW M. BLUMENFELD
  • Publication number: 20110200639
    Abstract: Methods for preventing or treating depression including a depression mediated by the thalamus. Depression, including a thalamically mediated depression, can be treated by peripheral administration of a botulinum toxin to or to the vicinity of a trigeminal sensory nerve, thereby preventing or treating the depression.
    Type: Application
    Filed: March 22, 2011
    Publication date: August 18, 2011
    Applicant: ALLERGAN, INC.
    Inventor: Andrew M. Blumenfeld
  • Patent number: 7981433
    Abstract: Botulinum toxin, among other presynaptic neurotoxins is used for the treatment and prevention of migraine and other headaches associated with vascular disorders. Presynaptic neurotoxins are delivered focally, targeting the sphenopalatine ganglion. Exemplary delivery is carried out by way of injection.
    Type: Grant
    Filed: May 21, 2010
    Date of Patent: July 19, 2011
    Assignee: Allergan, Inc.
    Inventor: Andrew M. Blumenfeld
  • Publication number: 20100124559
    Abstract: Described herein are methods of preventing, modulating and treating spasticity and maladaptive neuronal plasticity in patients having upper motor neuron lesions or have had a traumatic central nervous system event by early intervention methods. The methods comprise the step of administering a therapeutically effective amount of a botulinum toxin or derivative thereof to least a portion of a 1A sensory afferent of at least one muscle prior to development of spasticity or maladaptive neuronal plasticity becomes clinically apparent. The therapeutically effective amount of botulinum toxin administered to the 1A afferent of the muscle does not substantially affect the Golgi tendons therein.
    Type: Application
    Filed: October 13, 2009
    Publication date: May 20, 2010
    Applicant: ALLERGAN, INC.
    Inventors: Andrew M. BLUMENFELD, Ryan A. IRVINE
  • Patent number: 7655244
    Abstract: Botulinum toxin, among other presynaptic neurotoxins is used for the treatment and prevention of migraine and other headaches associated with vascular disorders. Presynaptic neurotoxins are delivered focally, targeting the nerve endings of the trigeminal nerve, the occipital nerve and the intranasal terminals of the parasympathetic fibers originating in the Sphenopalatine ganglion. The administration preferably targets the extracranial nerve endings of the trigeminal nerve in the temporal area, the extracranial occipital nerve endings in the occipital area, and the intranasal terminals of the trigeminal nerve and parasympathetic fibers originating in the Sphenopalatine ganglion. The delivery is carried out by way of injection or topically.
    Type: Grant
    Filed: December 7, 2005
    Date of Patent: February 2, 2010
    Assignee: Allergan, Inc.
    Inventor: Andrew M. Blumenfeld
  • Publication number: 20090252764
    Abstract: The present invention utilizes patient-specific landmarks in order to treat headache pain. In one aspect, the present invention relates to the administration of Clostridial toxins, such as a botulinum neurotoxin, to a patient suffering from a headache pain, where the location of administration of the botulinum toxin is based upon at least one suture line of the patient's skull.
    Type: Application
    Filed: April 3, 2008
    Publication date: October 8, 2009
    Inventor: Andrew M. Blumenfeld
  • Publication number: 20080199453
    Abstract: Disclosed herein are methods of using extracellular matrix digesting enzymes and neurotoxins, such as a Clostridial neurotoxins, to treat various medical conditions, such as overactive bladder, benign prostatic hyperplasia, hyperhidrosis, and cholecystitis for example.
    Type: Application
    Filed: February 15, 2008
    Publication date: August 21, 2008
    Inventors: Franklin D. Gaylis, Andrew M. Blumenfeld
  • Publication number: 20080199452
    Abstract: Disclosed herein are methods of using extracellular matrix digesting enzymes and neurotoxins, such as a Clostridial neurotoxins, to treat various medical conditions, such as overactive bladder, benign prostatic hyperplasia, hyperhidrosis, for example.
    Type: Application
    Filed: February 15, 2008
    Publication date: August 21, 2008
    Inventors: Franklin D. Gaylis, Andrew M. Blumenfeld
  • Publication number: 20040115139
    Abstract: Methods for facilitating various dental treatments, therapies and procedures by administration of a Clostridial toxin to a muscle or other tissue on the head or neck of a patient.
    Type: Application
    Filed: October 15, 2003
    Publication date: June 17, 2004
    Applicant: Allergan, Inc.
    Inventors: Howard I. Katz, Andrew M. Blumenfeld